0.00
0.00%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Kaleido Biosciences
Its shares trade under the ticker KLDO. It has been listed since 28 February 2019. In the fiscal year to 31 December 2021, it reported revenue of $1.1m and a net loss of $90.3m. At that date it held total assets of $50.1m and shareholders' equity of $10.6m.
Kaleido Biosciences, Inc. engages in the provision of healthcare services. The company is headquartered in Bedford, Massachusetts. The company went IPO on 2019-02-28. The Company’s product candidates are Microbiome Metabolic Therapies (MMTs), which are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the organ’s existing microbes. Its proprietary product platform includes ex vivo screening of microbiome samples from healthy volunteers, ex vivo testing of patient microbiome samples and advancement of its MMT candidates into non- Investigational New Drug Application (IND) human clinical studies. Its ex vivo screening process combines advances in drug discovery with microbiome science.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 28 Feb 2019
- Employees
- 82
- Website
- kaleido.com ↗
Leadership
Pay as last reported
- Mr. Theo Melas-KyriaziChairman of the Board, since 2019$146,563
- Dr. Bonnie BasslerIndependent Director$122,730
- Ms. Jean MixerIndependent Director$127,230
- Dr. Anne PrenerIndependent Director$118,730
- Dr. Anthony QuinnIndependent Director$124,730
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 45
- Environment
- 44
- Social
- 73
- Governance
- 17
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Kaleido Biosciences Inc has a strong portfolio of innovative biotechnological products, allowing them to cater to diverse customer needs.
- The company has a highly talented and experienced team of researchers and scientists, enabling them to develop cutting-edge solutions and stay at the forefront of the industry.
Weaknesses
- Kaleido Biosciences Inc heavily relies on partnerships and collaborations for research and development, which may result in limited control over the entire product development process.
- The company's current product range is relatively limited compared to some competitors, potentially hindering market share expansion.
Opportunities
- The growing demand for personalized medicine opens up new opportunities for Kaleido Biosciences Inc to develop customized solutions tailored to individual patients.
- The increasing investment in biotechnology research and development globally provides a favorable environment for the company to expand its product pipeline and enter new markets.
Threats
- The competitive landscape within the biopharmaceutical industry is intense, with many established players already dominating the market. This poses a threat to Kaleido Biosciences Inc's market penetration and growth.
- Regulatory challenges and stringent approval processes may delay the commercialization of the company's products and impact its ability to generate revenue.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.